Association of PCSK9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study

Cheng-Yuan Li; Wei-Ting Wang; Sheng-Hsiang Ma; Li-Wei Lo; Chen-Yi Wu; Wei-Chuan Chang; Yi-Ju Chen; Tai-Li Chen

doi:10.1093/bjd/ljae438

Association of PCSK9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study

Br J Dermatol. 2024 Nov 25:ljae438. doi: 10.1093/bjd/ljae438. Online ahead of print.

Authors

Cheng-Yuan Li^{1

2}, Wei-Ting Wang^{2

3}, Sheng-Hsiang Ma^{1

2

4}, Li-Wei Lo^{5

6}, Chen-Yi Wu^{1

2

4}, Wei-Chuan Chang⁷, Yi-Ju Chen⁸, Tai-Li Chen^{1

2}

Affiliations

¹ Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan.
² School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan.
³ Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taiwan.
⁴ Department of Public Health, Institute of Public Health, National Yang Ming Chao Tung University, Taipei, Taiwan.
⁵ Cardiovascular center, Department of Internal Medicine, Taipei Veterans General Hospital, Taiwan.
⁶ Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁷ Epidemiology and Biostatistics Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
⁸ Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan.

PMID: 39585798
DOI: 10.1093/bjd/ljae438

Abstract

Background: Growing evidence has shown that cholesterol metabolism abnormalities involve carcinogenesis. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors have been reported to inhibit tumor progression and prevent ultraviolet-related skin damage.

Objective: To investigate the association of PCSK9 inhibitors with the risk of nonmelanoma skin cancer (NMSC).

Methods: This retrospective cohort study analyzed data from the US Collaborative Network in the TriNetX database. Adults aged ≥40 years with atherosclerotic cardiovascular disease (ASCVD) under statin therapy between 2016 and 2022 were identified. A target trial design was used to compare the risk of NMSC, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), among patients additionally treated with PCSK9 inhibitors or continuing statin therapy (the control group). Each head-to-head comparison involved propensity score matching. Hazard ratios (HRs) were estimated using Cox proportional hazard models. Stratified analyses based on age, sex, Fitzpatrick skin type, and immune status were also performed.

Results: A total of 73,636 patients with ASCVD were analyzed. Compared with the control group, the ASCVD patients initiating PCSK9 inhibitors were associated with lower risks of NMSC (HR: 0.78; 95%CI: 0.71-0.87), BCC (HR: 0.78; 95%CI: 0.69-0.89), and cSCC (HR: 0.79; 95%CI: 0.67-0.93). Subanalyses revealed the reduced risk of NMSC observed with each PCSK9 inhibitor, namely, evolocumab and alirocumab. Stratified analyses showed similar results among patients aged 65-79 years, those more than 80 years, and male patients.

Conclusions: Our study indicated ASCVD patients with PCSK9 inhibitors have a lower risk of incident NMSC than those without PCSK9 inhibitors.

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].